Eisai’s anti-cancer agent LENVIMA receives orphan drug designation
Japanese pharmaceutical company Eisai has received orphan drug designation for its anti-cancer agent LENVIMA with a prospective indication for uterine…
Japanese pharmaceutical company Eisai has received orphan drug designation for its anti-cancer agent LENVIMA with a prospective indication for uterine…
Several countries in Europe have suspended the University of Oxford / AstraZeneca (AZ) Covid-19 vaccine completely or partially after several…